Searched for
MANKIND PHARMA LISTING
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...- Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Red alert: 15 stocks most vulnerable to FII selling as DIIs refuse to step inForeign institutional investors have divested approximately $53 billion from Indian equities since September 2024, leading to significant o...
- Is your portfolio FII-proof? 7 stocks Jefferies says can defy the $53 billion foreign selloffForeign investors have divested $53 billion from Indian equities since late 2024, leading to underperformance against emerging markets. Dom...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%It is not every day that you see crude oil prices moving higher and the Asian markets, including India, also inching higher. Now, as an inv...
- Market not much enthused by Mankind's BSV buyAfter initially cheering the deal, the stock market gave its thumbs-down to Mankind acquiring BSV at the premium valuations of eight times ...
- Block Deal: Hema CIPEF likely to sell around 1% stake in Mankind PharmaCapital Group held a 2.22% stake in the company as on March 31, 2024. In December last year, Capital Group divested a 3.14% stake in Mankin...
- D-Street newbie Mankind Pharma to be included in Nifty500, Nifty Midcap100 and other indicesMankind Pharma, which recently made its stock exchange debut, has been added to several Nifty indices, including Nifty500 and Nifty Midcap1...
- Mankind Pharma shares plunge over 5% as I-T department raids Delhi officeShares of Mankind Pharma dropped 5.5% following news of India's income tax department conducting searches at its Delhi office. Its shares a...
- Mankind Pharma rallies 32% on day 1At Tuesday's closing price, Mankind Pharma was valued at a price-to-earnings ratio of 43 times its FY22 earnings. Mankind is now India's fi...
- Mankind Pharma looking for selective acquisition opportunities: Rajiv JunejaMankind Pharma, a domestic-focused Indian pharmaceutical company is looking for selective acquisition opportunities that add value to its p...
- 31% listing day pop! Time to book profits in Mankind Pharma shares?Its shares are currently trading nearly 6.7% higher at Rs 1,387. The IPO received a strong response, with the issue subscribed for 15.32 ti...
- Macquarie initiates coverage on Mankind Pharma, sees 30% upsideMankind Pharma derives 98% of its revenue from the domestic pharma market. Within its domestic business, 90% of its revenue comes from pres...
- Mankind Pharma shares list at 20% premium over IPO priceThe IPO, valued at Rs 4,326 crore, received an overwhelming response, being subscribed for 15.32 times due to interest from qualified insti...
- Mankind Pharma IPO: What GMP signals ahead of listing on TuesdayMankind Pharma is set to list on May 9 with a premium of Rs 120 apiece according to grey market trends. The company is valued at a price-to...
- Mankind Pharma set for stellar debut on Tuesday, Street sees 8-10% listing premiumMankind Pharma's shares are commanding a premium of Rs 100-113 to its issue price of Rs 1,080 in the grey market. Research analysts predict...
- Mankind to venture into anti-psychoticsMankind Pharma, which registered the highest growth in the industry over the last one year, is venturing into the Rs 1,000-crore anti-psych...
Load More
